Description
Survodutide (BI 456906) is a dual agonist that activates GLP-1 and glucagon receptors. Unlike the Tirzepatide approach (GLP-1 plus GIP), Survodutide combines the classical incretin pathway with glucagon activation. Glucagon agonism is associated in research models with increased energy expenditure, enhanced lipolysis and improvements in liver function.
The compound has been investigated in an extensive clinical program since 2020. The SYNCHRONIZE Phase 3 trial series published initial data in April 2026: body weight reductions of 16.6 percent after 76 weeks, with reductions originating primarily from fat tissue. The LIVERAGE program runs in parallel for research on MASH and liver fibrosis, with FDA Breakthrough Therapy designation.
Pharmacokinetically, Survodutide is designed for weekly subcutaneous use in research protocols. The half-life is in the range of approximately five to six days. Survodutide was originally developed by Zealand Pharma and is being further investigated in pharmaceutical research by Boehringer Ingelheim.
Within the GLP-1 family in our catalog, Survodutide is one of the few compounds that introduces the glucagon pathway as a dual component. This makes it particularly interesting for research setups focused on lipid metabolism effects or hepatic markers.
You can order Survodutide in 10-vial packs at 5mg and 10mg per vial. Due to the higher potency in many research protocols, smaller vial sizes are sufficient.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Survodutide is considered generally well tolerated per study reports, although as a GLP-1/glucagon dual agonist the documented profile is shaped by gastrointestinal effects and is dose-dependent in the Phase 2 data.
Observed in studies and user reports:
- Gastrointestinal effects: nausea, vomiting, diarrhea and constipation are the most commonly documented observations, particularly at the start and with overly rapid dose escalation. Slow titration reduces the incidence.
- Appetite and fluids: the reduced appetite can lead to decreased food and fluid intake. The literature describes an elevated risk of dehydration.
- Heart rate: the literature documents mild increases in heart rate attributed to the glucagon component.
- Muscle mass and injection site: weight loss involves a portion of muscle mass alongside fat mass. Mild irritation at the injection site is documented.
- No long-term data: Survodutide is still within its clinical program. Robust data on very long-term use do not yet exist.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: Phase 2 trial - Lancet Diabetes & Endocrinology 2024: Phase 2 data on obesity research with dose finding.
- Dose-response effects on HbA1c and bodyweight reduction of survodutide vs semaglutide - Diabetologia 2023: Comparison of Survodutide against Semaglutide in type 2 diabetes research.
- Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial - JACC: Heart Failure 2024: Design paper for the phase 3 SYNCHRONIZE-CVOT trial: 4935 adults with a BMI of 27 or higher and increased cardiovascular risk are planned. The primary endpoint is time to first major adverse cardiovascular event. The paper reports design and rationale, not results.
